The Imaging X-ray Polarimetry Explorer (IXPE): Technical Overview

The Imaging X-ray Polarimetry Explorer (IXPE) will expand the information space for study of cosmic sources, by adding linear polarization to the properties (time, energy, and position) observed in x-ray astronomy. Selected in 2017 January as a NASA Astrophysics Small Explorer (SMEX) mission, IXPE will be launched into an equatorial orbit in 2021. The IXPE mission will provide scientifically meaningful measurements of the x-ray polarization of a few dozen sources in the 2-8 keV band, including polarization maps of several x-ray-bright extended sources and phase-resolved polarimetry of many bright pulsating x-ray sources

Design and thermal analysis of the cooling system of the Mu2e electromagnetic calorimeter at Fermilab

My research project has been the design of the cooling system of the Mu2e electromagnetic calorimeter and the development of the integration procedures of the system in the experimental area. I have dedicated my Master Thesis to the design of the calorimeter electronics cooling system of the front-end electronics. My research project has been to done completely the architecture of the front-end electronics cooling system, its integration on the electromagnetic calorimeter and to perform tests in order to verify the performances of the cooling system. I have also performed the thermal analysis of the front-end electronics and the photo-sensor

Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)Research in context

Summary: Background: Among interleukin-6 inhibitors suggested for use in COVID-19, there are few robust evidences for the efficacy of sarilumab. Herein, we evaluated the efficacy and safety of sarilumab in severe COVID-19. Methods: In this phase 3, open-labeled, randomized clinical trial, conducted at 5 Italian hospitals, adults with severe COVID-19 pneumonia (excluding mechanically ventilated) were randomized 2:1 to receive intravenous sarilumab (400 mg, repeatable after 12 h) plus standard of care (SOC) (arm A) or to continue SOC (arm B). Randomization was web-based. As post-hoc analyses, the participants were stratified according to baseline inflammatory parameters. The primary endpoint was analysed on the modified Intention-To-Treat population, including all the randomized patients who received any study treatment (sarilumab or SOC). It was time to clinical improvement of 2 points on a 7-points ordinal scale, from baseline to day 30. We used Kaplan Meier method and log-rank test to compare the primary outcome between two arms, and Cox regression stratified by clinical center and adjusted for severity of illness, to estimate the hazard ratio (HR). The trial was registered with EudraCT (2020-001390-76). Findings: Between May 2020 and May 2021, 191 patients were assessed for eligibility, of whom, excluding nine dropouts, 176 were assigned to arm A (121) and B (55). At day 30, no significant differences in the primary endpoint were found (88% [95% CI 81–94] in arm A vs 85% [74–93], HR 1.07 [0.8–1.5] in arm B; log-rank p = 0.50). After stratifying for inflammatory parameters, arm A showed higher probability of improvement than B without statistical significance in the strata with C reactive protein (CRP) < 7 mg/dL (88% [77–96] vs 79% [63–91], HR 1.55 [0.9–2.6]; log-rank p = 0.049) and in the strata with lymphocytes <870/mmc (90% [79–96]) vs (73% [55–89], HR 1.53 [0.9–2.7]; log-rank p = 0.058). Overall, 39/121 (32%) AEs were reported in arm A and 14/55 (23%) in B (p = 0.195), while serious AEs were 22/121 (18%) and 7/55 (11%), respectively (p = 0.244). There were no treatment-related deaths. Interpretation: The efficacy of sarilumab in severe COVID-19 was not demonstrated both in the overall and in the stratified for severity analysis population. Exploratory analyses suggested that subsets of patients with lower CRP values or lower lymphocyte counts might have had benefit with sarilumab treatment, but this finding would require replication in other studies. The relatively low rate of concomitant corticosteroid use, could partially explain our results. Funding: This study was supported by INMI “Lazzaro Spallanzani” Ricerca Corrente Linea 1 on emerging and reemerging infections, funded by Italian Ministry of Health

The Instrument of the Imaging X-Ray Polarimetry Explorer

While X-ray spectroscopy, timing, and imaging have improved much since 1962 when the first astronomical nonsolar source was discovered, especially wi the launch of the Newton/X-ray Multi-Mirror Mission, Rossi/X-ray Timing Explorer, and Chandra/Advanced X-ray Astrophysics Facility, the progress of X-ray polarimetry has been meager. This is in part due to the lack of sensitive polarization detectors, which in turn is a result of the fate of approved missions and because celestial X-ray sources appear less polarized than expected. Only one positive measurement has been available until now: the Orbiting Solar Observatory measured the polarization of the Crab Nebula in the 1970s. The advent of microelectronics techniques has allowed for designing a detector based on the photoelectric effect of gas in an energy range where the optics are efficient at focusing in X-rays. Here we describe the instrument, which is the major contribution of the Italian collaboration to the Small Explorer mission called IXPE, the Imaging X-ray Polarimetry Explorer, which will launch in late 2021. The instrument is composed of three detector units based on this technique and a detector service unit. Three mirror modules provided by Marshall Space Flight Center focus X-rays onto the detectors. We show the technological choices, their scientific motivation, and results from the calibration of the instrument. IXPE will perform imaging, timing, and energy-resolved polarimetry in the 2–8 keV energy band opening this window of X-ray astronomy to tens of celestial sources of almost all classes

The Imaging X-Ray Polarimetry Explorer (IXPE): Technical Overview II

The Imaging X-ray Polarimetry Explorer (IXPE) will add polarization to the properties (time, energy, and position) observed in x-ray astronomy. A NASA Astrophysics Small Explorer (SMEX) in partnership with the Italian Space Agency (ASI), IXPE will measure the 28-keV polarization of a few dozen sources during the first 2 years following its 2021 launch. The IXPE Observatory includes three identical x-ray telescopes, each comprising a 4-m-focal-length (grazingincidence) mirror module assembly (MMA) and a polarization-sensitive (imaging) detector unit (DU), separated by a deployable optical bench. The Observatorys Spacecraft provides typical subsystems (mechanical, structural, thermal, power, electrical, telecommunications, etc.), an attitude determination and control subsystem for 3-axis stabilized pointing, and a command and data handling subsystem communicating with the science instrument and the Spacecraft subsystems

The Imaging X-Ray Polarimetry Explorer (IXPE): technical overview II

The Imaging X-ray Polarimetry Explorer (IXPE) will add polarization to the properties (time, energy, and position) observed in x-ray astronomy. A NASA Astrophysics Small Explorer (SMEX) in partnership with the Italian Space Agency (ASI), IXPE will measure the 2–8-keV polarization of a few dozen sources during the first 2 years following its 2021 launch. The IXPE Observatory includes three identical x-ray telescopes, each comprising a 4-m-focal-length (grazingincidence) mirror module assembly (MMA) and a polarization-sensitive (imaging) detector unit (DU), separated by a deployable optical bench. The Observatory’s Spacecraft provides typical subsystems (mechanical, structural, thermal, power, electrical, telecommunications, etc.), an attitude determination and control subsystem for 3-axis stabilized pointing, and a command and data handling subsystem communicating with the science instrument and the Spacecraft subsystems